Search

IQVIA Holdings Inc

Затворен

СекторЗдравеопазване

236.14 -2.23

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

237.02

Максимум

243.97

Ключови измерители

By Trading Economics

Приходи

-17M

258M

Продажби

217M

4.4B

P/E

Средно за сектора

30.137

57.002

EPS

2.75

Марж на печалбата

5.907

Служители

94,000

EBITDA

-18M

790M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+13.12% upside

Дивиденти

By Acuity

Следващи печалби

27.10.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

4.2B

40B

Предишно отваряне

238.37

Предишно затваряне

236.14

Настроения в новините

By Acuity

50%

50%

152 / 340 Класиране в Healthcare

IQVIA Holdings Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.08.2026 г., 19:46 ч. UTC

News

IQVIA Holdings reported $3.2 billion in new bookings for Q2 2026, but shares are trading lower despite strong growth metrics.

11.08.2026 г., 22:46 ч. UTC

IQVIA Holdings Inc shares are trading higher in after-market hours, showing strength despite a broader market decline influenced by rising crude oil prices.

10.08.2026 г., 23:01 ч. UTC

IQVIA Holdings Inc is trading higher in after-market hours, maintaining a steady upward trajectory and positioning above its 20-day moving average.

8.08.2026 г., 00:01 ч. UTC

IQVIA Holdings Inc shares are lower in after-market hours amid broader market concerns over Federal Reserve interest rate policies and a recent weak jobs report.

7.08.2026 г., 23:01 ч. UTC

IQVIA Holdings Inc shares are lower in after-market hours, continuing a decline since Friday's close with no specific news identified for the drop.

6.08.2026 г., 20:06 ч. UTC

IQVIA Holdings Inc shares are declining today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain this movement.

5.08.2026 г., 20:03 ч. UTC

Correlated Moves
News

IQVIA Holdings announced a collaboration with Medera to advance cardiac gene therapies. Positive sentiment from this partnership likely supported shares trading higher today.

4.08.2026 г., 23:01 ч. UTC

News

IQVIA Holdings Inc announced a collaboration with Medera to enhance cardiac gene therapies. Shares declined during after-market trading, continuing a trend of lower closes.

3.08.2026 г., 20:06 ч. UTC

IQVIA Holdings Inc. shares are lower today, breaking a trend of higher closes since Friday. No specific company news was identified to explain the move.

31.07.2026 г., 19:16 ч. UTC

News

Shares of IQVIA Holdings lower after first-quarter results.

30.07.2026 г., 23:02 ч. UTC

IQVIA Holdings Inc shares are higher in after-market trading, reflecting positive momentum since Thursday's close, despite no specific news driving the movement.

29.07.2026 г., 22:06 ч. UTC

Correlated Moves

IQVIA Holdings shares declined in after-hours trading, reflecting broader market unease following the Federal Reserve's decision to maintain interest rates.

28.07.2026 г., 20:51 ч. UTC

IQVIA Holdings Inc is trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

27.07.2026 г., 23:12 ч. UTC

IQVIA Holdings Inc. shares are higher in after-market trading, tracking broader gains in European markets, including a rise in the DAX 30 Index.

23.07.2026 г., 20:03 ч. UTC

Correlated Moves

IQVIA Holdings Inc shares are higher, supported by a rise in Thermo Fisher Scientific Inc's stock and positive sentiment in the life sciences sector.

22.07.2026 г., 16:36 ч. UTC

IQVIA Holdings Inc shares are lower today, continuing a trend of declines. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

21.07.2026 г., 19:06 ч. UTC

Social Media

Shares of IQVIA Holdings Inc are lower following disappointing first-quarter results. Unusual call options activity exceeding $2 million indicates heightened investor interest.

Сравнение с други в отрасъла

Ценова промяна

IQVIA Holdings Inc Прогноза

Ценова цел

By TipRanks

13.12% нагоре

12-месечна прогноза

Среден 273.43 USD  13.12%

Висок 300 USD

Нисък 240 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за IQVIA Holdings Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

15

Купи

1

Задържане

0

Продай

Настроение

By Acuity

152 / 340 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat